Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06124924 · ClinicalTrials.gov registry record · Early Phase 1
SGLT2 Inhibitors After Acute Kidney Injury With Indications Pilot
A Early Phase 1 study, sponsored by University of Minnesota.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
NCT06124924: Clinical Trial Early Phase 1 study, sponsored by University of Minnesota.
NCT06124924 is a Early Phase 1 study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 1 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06124924, a Early Phase 1 study, was terminated before completion, sponsored by University of Minnesota.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
SGLT2i have been shown to reduce risk for mortality, progression of chronic kidney disease, and cardiovascular outcomes in these populations. Yet, because SGLT2i can have an acute hemodynamic effect on kidney function, in clinical practice providers are wary of providing these medications to patients who have established indications but recently had acute kidney injury (AKI). This is a pilot interventional study to collect process-data (measures of recruitment and measures of adherence) that can be used to establish feasibility for a larger pilot randomized trial in the future. The study aims to conduct a small randomized intervention trial with two arms, with approximately 10-12 patients in the intervention arm and 5-6 in the control arm. The intervention will be providing a prescription for a SGLT2i based on established criteria for this FDA-approved class of drugs, and the control will be usual care (through which, control arm participants will also have access to this FDA-approved class of drugs - expect receipt of a SGLT2i in the control arm to be rare, but a degree of crossover will be expected).
Primary Outcome
proportion of patients in each arm of the study using a SGLT2i at one month of follow-up.
Interventions
- DRUG SGLT2 inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2024-08-16 |
| Phase | Early Phase 1 |
Why NCT06124924 stopped before completion
NCT06124924 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which SGLT2 inhibitor is the first listed.
NCT06124924 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06124924 about?
NCT06124924 is a clinical study titled "SGLT2 Inhibitors After Acute Kidney Injury With Indications Pilot". SGLT2i have been shown to reduce risk for mortality, progression of chronic kidney disease, and cardiovascular outcomes in these populations. Yet, because SGLT2i can have an acute hemodynamic effect on kidney function, in clinical practice providers are wary of providing these medications to patient...
What is the current status of trial NCT06124924?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2024-04-01. Estimated completion is 2024-08-16.
What interventions are being tested in trial NCT06124924?
The interventions under investigation include: SGLT2 inhibitor (DRUG).
Who is sponsoring clinical trial NCT06124924?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06124924's enrollment target sits among peer trials
1 1985th of 2000 the lowest of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI